CORRECTION: Novo Nordisk Ticker is "NVO"
$NVO
$NVX
Biotechnology: Pharmaceutical Preparations
Health Care
Industrial Machinery/Components
Miscellaneous
CORRECTION: Novo Nordisk Ticker is "NVO"
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 5/30/2024 | $4.00 | Buy | Chardan Capital Markets | |
| 5/30/2024 | $156.00 | Buy | Goldman | |
| 4/12/2024 | $163.00 | Outperform | BMO Capital Markets | |
| 1/23/2024 | $120.00 | Overweight | Morgan Stanley | |
| 1/16/2024 | Neutral | UBS | ||
| 12/1/2023 | $120.00 | Overweight | Cantor Fitzgerald | |
| 10/2/2023 | $110.00 | Buy | Argus | |
| 7/14/2023 | Buy | HSBC Securities |
BRISBANE, Australia, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ:NVX, ASX: NVX))) ("NOVONIX" or the "Company"), a leading battery materials and technology company, today announced it will host a webcast on Thursday, October 5th, 2023 at 8:30 a.m. AEDT to provide a business update and discuss recent operational milestones. During the webcast, NOVONIX CEO, Dr. Chris Burns will provide an in-depth technical review and an update across the business including Battery Technology Solutions, Anode Materials and Cathode Materials. More specifically, this event will cover recent milestones and provide an update on the Company's progress in growing its high-performance synthetic gra
Chardan Capital Markets initiated coverage of Novonix Limited with a rating of Buy and set a new price target of $4.00
Goldman initiated coverage of Novo Nordisk A/S with a rating of Buy and set a new price target of $156.00
BMO Capital Markets initiated coverage of Novo Nordisk A/S with a rating of Outperform and set a new price target of $163.00
SC 13G - NOVONIX Ltd (0001859795) (Subject)
For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr
Offtake for NOVONIX's high-performance synthetic graphite material to be supplied to Stellantis' cell manufacturing partners in North AmericaAgreement for up to a target volume of 115,000 tonnes of synthetic graphite material from 2026-2031 BRISBANE, Australia, Nov. 10, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ:NVX, ASX: NVX)) ("NOVONIX" or the "Company"), a leading battery materials and technology company, and Stellantis NV ("Stellantis"), a leading automotive company, today announced the signing of a binding offtake agreement for a minimum of 86,250 tonnes, up to a target volume of 115,000 tonnes of high-performance synthetic graphite material. The material will be supplied to St
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced positive results demonstrating the anti-inflammatory potential of our anti-CD3 antibody (foralumab) in combination with semaglutide, a GLP-1 agonist marketed by Novo Nordisk (NYSE:NVO) under the brand names Ozempic and Wegovy. The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO
USA News Group News CommentaryIssued on behalf of PlantX Life Inc. VANCOUVER, BC, Oct. 24, 2024 /PRNewswire/ -- USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it's no wonder why analysts at SNS Insider are projecting the Weight Loss Drugs Market to grow at a whopping 43.73% CAGR through 2032. It's one of the fastest growing markets in pharmaceuticals, with nearly one in four employers saying they're either somewhat or very likely to begin covering the cost of anti-obesity medications within the next year. Health and wellness companies are responding in kind, with recent market developments coming
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
BRISBANE, Australia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ:NVX, ASX: NVX))), a leading battery materials and technology company, is pleased to announce that Robert Long will be appointed as the Company's Chief Financial Officer (CFO) effective September 1, 2024. Mr. Long brings over 25 years of experience in finance and executive leadership with both public and private companies. The Company previously announced that CFO Nick Liveris will transition to the Company's Board of Directors upon the appointment of a new CFO. Mr. Liveris will be appointed to the Board of Directors effective September 1, 2024. To ensure a smooth transition of the CFO role to Mr. Long, Ron
BRISBANE, Australia, May 22, 2024 (GLOBE NEWSWIRE) -- NOVONIX Limited (NASDAQ:NVX, ASX: NVX))) ("NOVONIX" or "the Company"), a leading battery materials and technology company, today announced that Chief Financial Officer ("CFO"), Nick Liveris, will retire from his executive role and transition to a non-executive role on NOVONIX's Board of Directors, effective on the appointment of a new CFO. The Company has begun the process of recruiting a new CFO who will work closely with Mr. Liveris to ensure a successful transition of the role. Mr. Liveris has decided to retire from the executive role at NOVONIX to work full time with the Liveris Family Office, through which he will continue t
6-K - NOVO NORDISK A S (0000353278) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
6-K - NOVO NORDISK A S (0000353278) (Filer)
Whales with a lot of money to spend have taken a noticeably bearish stance on Novo Nordisk. Looking at options history for Novo Nordisk (NYSE:NVO) we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $155,555 and 5, calls, for a total amount of $255,360. What's The Price Target? Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $100.0 to $175.0 for Novo Nordisk during the past quarter. Analyzing Volume & Open Interest Assessing
The National Health Service (NHS) has prescribed Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy far less often than anticipated, struggling with a shortage of weight management clinics required to distribute the popular treatment. Since its launch, the drug has been prescribed just 3,300 times, significantly below the 13,500 patients expected to receive it in its first year, according to a Financial Times analysis of NHS England data. Demand for Wegovy is set to increase following the Medicines and Healthcare Products Regulatory Agency’s (MHRA) approval for its use in reducing the risk of serious heart problems or strokes in overweight and obese adults. Despite this, the drug